Category Archives: TRIPS

South Centre statement on EU-MERCOSUR trade negotiations

Source: http://www.bilaterals.org South Centre statement on EU-MERCOSUR trade negotiations EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights. The South Centre is deeply concerned over intellectual property rights (IPRs) provisions put forward … Continue reading

Posted in EU- Mercosur FTA, IPR Enforcement, TRIPS plus, Uncategorized | Leave a comment

Medicines Excitement in the Netherlands – New Health Minister announces firm action on “absurd” medicines pricing and gets the European Medicines Agency.

The new Minister of Health of the Netherlands, Bruno Bruins, came in guns blazing when he put the pharmaceutical industry on notice and announced on 22 November to “change the rules of the game” to tackle, what he called “absurd” … Continue reading

Posted in Compulsory Licensing, Uncategorized | Leave a comment

Rethinking IP in the TPP: Canadian Government Plays Key Role in Suspending Unbalanced Patent and Copyright Rules

Source: http://www.michaelgeist.ca/2017/11/rethinking-ip-in-the-tpp/ Years of disappointment in trade negotiations have left many Canadian intellectual property watchers hoping for the best, but expecting the worst when it comes to the IP provisions in trade deals. In earlier talks, Canadian negotiators would often advocate … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent Term Extension, TPP, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Time for costly medicine monopolies to go from TPP trade talks

Source: Conversation.com |November 9, 2017 Negotiators from 11 countries have been racing to resurrect the near-dead Trans-Pacific Partnership Agreement before the Asia-Pacific Economic Cooperation (APEC) summit this weekend. The latest plan to get the controversial trade deal up and running … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, Patent, TPP, Uncategorized | Leave a comment

Gilead’s Patents on Hepatitis C Drug Challenged by Consumer Group

Source: Bloomberg Gilead Sciences Inc.’s U.S. patents on the blockbuster $84,000 hepatitis C treatment Sovaldi were challenged by a consumer group that’s battled the drugmaker around the world over the pricing.  The Initiative for Medicines, Access & Knowledge, a nonprofit focused on … Continue reading

Posted in Cancer, Evergreening, Hepatitis C, Patent, Uncategorized | Leave a comment

Greek health minister takes issue with Roche’s withdrawal of cancer medicine due to mandatory, retroactive discount

Source: EndPoints News Drug prices are not just a US problem. Greece’s minister of health on Tuesday expressed dismay over Roche’s decision to withdraw a cancer medicine because of a new mandatory discount imposed by the country. Greek health minister … Continue reading

Posted in Cancer, Compulsory Licensing, Patent, TRIPS, Uncategorized | 1 Comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment